CoChat

Sotorasib: First Approval

Open access
Blair, Hannah A. · 2021 · Drugs

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40265-021-01574-2

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Figures

Key milestones in the development of sotorasib for the treatment of KRAS G12C-mutated non-small cell lung cancer. MAA Market Authorisation Application, NDA New Drug Application
Key milestones in the development of sotorasib for the treatment of KRAS G12C-mutated non-small cell lung cancer. MAA Market Authorisation Application, NDA New Drug ApplicationCC BY-NC · PubMed Central
Chemical structure of sotorasib
Chemical structure of sotorasibCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 9

  1. Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.
  2. Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.
  3. Amgen. FDA grants sotorasib priority review designation for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer [media release]. 16 Feb 2021. https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.
  4. Cardona P, Simiens M, Purkis J, et al. An open-label study to evaluate the effect of omeprazole on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-009]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
  5. Cardona P, Spring M, Purkis J, et al. An open-label study to evaluate the effect of single and multiple doses of rifampin on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-010]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
  6. Vuu I, Simiens M, Purkis J, et al. A phase I, open-label study to evaluate drug-drug interactions between metformin and sotorasib (AMG 510) in healthy subjects [abstract no. PIII-018]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S50.
  7. Cardona P, Spring M, Purkis J, et al. An open-label study to evaluate the effect of sotorasib (AMG 510) on digoxin pharmacokinetics in healthy subjects [abstract no. PII-011]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
  8. Guardant Health. Guardant360® CDx receives FDA approval as first and only liquid biopsy companion diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C inhibitor for use in advanced non-small cell lung cancer [media release]. 28 May 2021. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx.
  9. QIAGEN. QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer [media release]. 28 May 2021. https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Launches-First-FDA-approved-Tissue-Companion-Diagnostic-to-Identify-the-KRAS-G12C-Mutation-in-NSCLC-Tumours-and-Expand-Precision-Medicine-Options-in-Lung-Cancer/default.aspx.

Cited by

See all 267

Metadata

Authors
Blair, H. A.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Blair, Hannah A.
Venue
Drugs
Published
2021-08-06
Volume
81
Issue
13
Pages
1573-1579
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3193019540
Cited by
241
References
11
Citations by year
2026: 39 · 2025: 45 · 2024: 53 · 2023: 46 · 2022: 53 · 2021: 5
FWCI
25.39
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
sotorasib, KRAS G12C mutation, non-small cell lung cancer, drug approval, accelerated approval, colorectal cancer, solid tumors, drug development milestones
MeSH terms
Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Piperazines, Pyridines, Pyrimidines, United States, United States Food and Drug Administration, Drug Approval, ras Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sotorasib: First Approval. https://app.cochat.ai/papers/10.1007/s40265-021-01574-2
The paper
Blair, H. A. (2021). Sotorasib: First Approval. Drugs. https://doi.org/10.1007/s40265-021-01574-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.